[go: up one dir, main page]

CL2022001189A1 - Anticuerpos para cd40. (divisional de solicitud n° 2017003427) - Google Patents

Anticuerpos para cd40. (divisional de solicitud n° 2017003427)

Info

Publication number
CL2022001189A1
CL2022001189A1 CL2022001189A CL2022001189A CL2022001189A1 CL 2022001189 A1 CL2022001189 A1 CL 2022001189A1 CL 2022001189 A CL2022001189 A CL 2022001189A CL 2022001189 A CL2022001189 A CL 2022001189A CL 2022001189 A1 CL2022001189 A1 CL 2022001189A1
Authority
CL
Chile
Prior art keywords
antibodies
application divisional
riib
antigen
bind
Prior art date
Application number
CL2022001189A
Other languages
English (en)
Inventor
Aaron P Yamniuk
Bryan C Barnhart
Brigitte Devaux
Shannon L Okada
Brenda L Stevens
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56322325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2022001189(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CL2022001189A1 publication Critical patent/CL2022001189A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere anticuerpos agonistas, o porciones de unión al antígeno del mismo que se unen a CD40 humano. Tales anticuerpos comprenden opcionalmente regiones Fc con especificidad mejorada para Fc?RIIb. La invención también proporciona métodos para el tratamiento de cáncer o infección crónica administrando los anticuerpos de la invención a un sujeto en necesidad del mismo.
CL2022001189A 2015-06-29 2022-05-04 Anticuerpos para cd40. (divisional de solicitud n° 2017003427) CL2022001189A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29
US201562252615P 2015-11-09 2015-11-09

Publications (1)

Publication Number Publication Date
CL2022001189A1 true CL2022001189A1 (es) 2023-01-20

Family

ID=56322325

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003427A CL2017003427A1 (es) 2015-06-29 2017-12-28 Anticuerpos para cd40
CL2022001189A CL2022001189A1 (es) 2015-06-29 2022-05-04 Anticuerpos para cd40. (divisional de solicitud n° 2017003427)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017003427A CL2017003427A1 (es) 2015-06-29 2017-12-28 Anticuerpos para cd40

Country Status (18)

Country Link
US (4) US20180142030A1 (es)
EP (1) EP3313880B1 (es)
JP (2) JP7350467B2 (es)
KR (1) KR102671348B1 (es)
CN (2) CN107771184B (es)
AU (2) AU2016285913B2 (es)
BR (1) BR112017027549A2 (es)
CA (1) CA2990012A1 (es)
CL (2) CL2017003427A1 (es)
CO (1) CO2018000809A2 (es)
EA (1) EA035268B1 (es)
ES (1) ES3039629T3 (es)
HK (1) HK1252666A1 (es)
IL (1) IL256499B (es)
MX (2) MX395257B (es)
PE (1) PE20180315A1 (es)
WO (1) WO2017004006A1 (es)
ZA (1) ZA201708704B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3556774T (pt) 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizações
CA2957146A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
UY36757A (es) * 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CN109069621B (zh) 2015-09-04 2022-09-06 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
CN109071655B (zh) 2016-03-04 2022-08-12 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
EP4371570A3 (en) 2016-06-08 2024-07-17 Xencor, Inc. Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
WO2017220988A1 (en) 2016-06-20 2017-12-28 Kymab Limited Multispecific antibodies for immuno-oncology
AR111830A1 (es) 2017-05-25 2019-08-21 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
EP3632932A4 (en) 2017-06-01 2021-08-18 Jiangsu Hengrui Medicine Co. Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
EP3732198A1 (en) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anti-cd40 antibodies and uses thereof
EA202092265A1 (ru) * 2018-03-23 2020-12-24 Эли Лилли Энд Компани Антитела против cd137 для комбинации с антителами против pd-l1
CA3105875A1 (en) * 2018-07-20 2020-01-23 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
KR20210040080A (ko) * 2018-07-26 2021-04-12 브리스톨-마이어스 스큅 컴퍼니 암의 치료를 위한 lag-3 조합 요법
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
TW202039558A (zh) * 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
JP7535060B2 (ja) 2019-04-10 2024-08-15 ナンカイ ユニバーシティ 抗ｃｄ４０抗体およびその使用
EP4118118A1 (en) 2020-03-09 2023-01-18 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
AU2021268885B2 (en) * 2020-05-06 2025-02-20 Navicure Biopharmaceuticals Limited Fusion proteins for immunotherapy against cancer and infectious diseases
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
US20240336693A1 (en) * 2021-08-10 2024-10-10 Apexigen, Inc. Biomarkers for cd40 agonist therapy
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
EP3431993A1 (en) * 2010-12-20 2019-01-23 The Rockefeller University Modulating agonistic tnfr antibodies
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
BR112016007112A2 (pt) 2013-12-20 2017-09-19 Hoffmann La Roche Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
EP3122779B1 (en) 2014-03-24 2019-05-22 Cancer Research Technology Limited Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
US20170233485A1 (en) * 2014-08-18 2017-08-17 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof
UY36757A (es) * 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CN109071655B (zh) * 2016-03-04 2022-08-12 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体

Also Published As

Publication number Publication date
CA2990012A1 (en) 2017-01-05
AU2016285913A1 (en) 2018-02-15
WO2017004006A1 (en) 2017-01-05
MX2017016253A (es) 2018-04-20
US20210054091A1 (en) 2021-02-25
KR20180021834A (ko) 2018-03-05
US20180142030A1 (en) 2018-05-24
BR112017027549A2 (pt) 2018-09-11
MX395257B (es) 2025-03-25
US10844130B2 (en) 2020-11-24
KR102671348B1 (ko) 2024-05-30
EA035268B1 (ru) 2020-05-22
CN107771184B (zh) 2022-11-01
ZA201708704B (en) 2019-08-28
AU2022228155A1 (en) 2022-11-10
US20240336695A1 (en) 2024-10-10
IL256499B (en) 2021-12-01
IL256499A (en) 2018-02-28
EP3313880A1 (en) 2018-05-02
CN107771184A (zh) 2018-03-06
EP3313880B1 (en) 2025-08-06
MX2022002504A (es) 2022-04-06
HK1252666A1 (zh) 2019-05-31
CO2018000809A2 (es) 2018-04-19
CL2017003427A1 (es) 2018-05-04
ES3039629T3 (en) 2025-10-23
JP2022028666A (ja) 2022-02-16
US20190248911A1 (en) 2019-08-15
JP7350467B2 (ja) 2023-09-26
PE20180315A1 (es) 2018-02-09
JP2018526978A (ja) 2018-09-20
AU2016285913B2 (en) 2022-06-16
EA201890175A1 (ru) 2018-06-29
CN115838427A (zh) 2023-03-24

Similar Documents

Publication Publication Date Title
CL2022001189A1 (es) Anticuerpos para cd40. (divisional de solicitud n° 2017003427)
UY36757A (es) Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
MX2015012644A (es) Tratamiento de cataplejia.
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
ECSP17008984A (es) Tratamientos conjuntos con anticuerpos anti cd40
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
EA201791710A1 (ru) Антитела к транстиретину
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
UY35493A (es) Métodos para el tratamiento de la osteogénesis imperfecta
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
CO2017008469A2 (es) Anticuerpos anti-transtiretina
CL2016001753A1 (es) Anticuerpo monoclonal humanizado que se une específicamente a netrina-1, composiciones farmacéuticas y usos del anticuerpo para el tratamiento del cáncer
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2017001686A (es) Anticuerpos anti-ceramida.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2020004074A (es) Producto de combinacion para el tratamiento de cancer.
MX2019014291A (es) Metodo de tratamiento.
MX378452B (es) Anticuerpos monoclonales anti-+)--metanfetamina.
MX2018001684A (es) Metodo de curacion de heridas.
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.